High-Throughput Assessment of Kinome-wide Activation States

Abelin, 2016, Reduced-representation phosphosignatures measured by quantitative targeted ms capture cellular states and enable large-scale comparison of drug-induced phenotypes, Mol. Cell. Proteomics, 15, 1622, 10.1074/mcp.M116.058354 Annibaldi, 2018, Checkpoints in TNF-induced cell death: implications in inflammation and cancer, Trends Mol. Med., 24, 49, 10.1016/j.molmed.2017.11.002 Atkinson, 2003, Tec regulates platelet activation by GPVI in the absence of Btk, Blood, 102, 3592, 10.1182/blood-2003-04-1142 Bantscheff, 2007, Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors, Nat. Biotechnol., 25, 1035, 10.1038/nbt1328 Batth, 2014, Off-line high-pH reversed-phase fractionation for in-depth phosphoproteomics, J. Proteome Res., 13, 6176, 10.1021/pr500893m Blume-Jensen, 2001, Oncogenic kinase signalling, Nature, 411, 355, 10.1038/35077225 Chang, 2012, Protein significance analysis in selected reaction monitoring (SRM) measurements, Mol. Cell. Proteomics, 11, 10.1074/mcp.M111.014662 Choi, 2014, MSstats: an R package for statistical analysis of quantitative mass spectrometry-based proteomic experiments, Bioinformatics, 30, 2524, 10.1093/bioinformatics/btu305 Collins, 2018, Proteomic analysis defines kinase taxonomies specific for subtypes of breast cancer, Oncotarget, 9, 15480, 10.18632/oncotarget.24337 Cox, 2008, MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification, Nature Biotechnology, 26, 1367, 10.1038/nbt.1511 Cristobal, 2012, In-house construction of a UHPLC system enabling the identification of over 4000 protein groups in a single analysis, Analyst, 137, 3541, 10.1039/c2an35445d de Graaf, 2015, Signal transduction reaction monitoring deciphers site-specific PI3K-mTOR/MAPK pathway dynamics in oncogene-induced senescence, J. Proteome Res., 14, 2906, 10.1021/acs.jproteome.5b00236 Degterev, 2008, Identification of RIP1 kinase as a specific cellular target of necrostatins, Nat. Chem. Biol., 4, 313, 10.1038/nchembio.83 Desiere, 2006, The PeptideAtlas project, Nucleic Acids Res., 34, D655, 10.1093/nar/gkj040 Ding, 2011, Tyrosine phosphorylation profiling in FGF-2 stimulated human embryonic stem cells, PLoS One, 6, e17538, 10.1371/journal.pone.0017538 Donnelly, 2014, P38 MAPK contributes to resistance and invasiveness of HER2- overexpressing breast cancer, Curr. Med. Chem., 21, 501, 10.2174/0929867320666131119155023 Edwards, 2011, Too many roads not taken, Nature, 470, 163, 10.1038/470163a Fabbro, 2015, Ten things you should know about protein kinases: IUPHAR Review 14, Br. J. Pharmacol., 172, 2675, 10.1111/bph.13096 Garay, 2012, Omics and therapy - a basis for precision medicine, Mol. Oncol., 6, 128, 10.1016/j.molonc.2012.02.009 Gross, 2015, Targeting cancer with kinase inhibitors, J. Clin. Invest., 125, 1780, 10.1172/JCI76094 Grover, 2018, Platelet signaling pathways and new inhibitors, Arterioscler. Thromb. Vasc. Biol., 38, e28, 10.1161/ATVBAHA.118.310224 Gu, 2009, Protein kinase A activation confers resistance to trastuzumab in human breast cancer cell lines, Clin. Cancer Res., 15, 7196, 10.1158/1078-0432.CCR-09-0585 Guo, 2011, Global molecular dysfunctions in gastric cancer revealed by an integrated analysis of the phosphoproteome and transcriptome, Cell. Mol. Life Sci., 68, 1983, 10.1007/s00018-010-0545-x Holler, 2000, Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule, Nat. Immunol., 1, 489, 10.1038/82732 Käll, 2007, Semi-supervised learning for peptide identification from shotgun proteomics datasets, Nat. Methods, 4, 923, 10.1038/nmeth1113 Kemper, 2015, Intra- and inter-tumor heterogeneity in a vemurafenib-resistant melanoma patient and derived xenografts, EMBO Mol. Med., 7, 1104, 10.15252/emmm.201404914 Kostenko, 2012, Tumour promoting and suppressing roles of the atypical MAP kinase signalling pathway ERK3/4-MK5, J. Mol. Signal., 7, 9, 10.1186/1750-2187-7-9 Lachmann, 2009, KEA: kinase enrichment analysis, Bioinformatics, 25, 684, 10.1093/bioinformatics/btp026 Lahiry, 2010, Kinase mutations in human disease: interpreting genotype-phenotype relationships, Nat. Rev. Genet., 11, 60, 10.1038/nrg2707 Maclean, 2010, Effect of collision energy optimization on the measurement of peptides by selected reaction monitoring (SRM) mass spectrometry, Anal. Chem., 82, 10116, 10.1021/ac102179j MacLean, 2010, Skyline: an open source document editor for creating and analyzing targeted proteomics experiments, Bioinformatics, 26, 966, 10.1093/bioinformatics/btq054 Manning, 2002, The protein kinase complement of the human genome, Science, 298, 1912, 10.1126/science.1075762 Miller, 2008, Linear motif atlas for phosphorylation-dependent signaling, Sci. Signal., 1, ra2, 10.1126/scisignal.1159433 Nesvizhskii, 2005, Interpretation of shotgun proteomic data: the protein inference problem, Mol. Cell. Proteomics, 4, 1419, 10.1074/mcp.R500012-MCP200 Nolen, 2004, Regulation of protein kinases; controlling activity through activation segment conformation, Mol. Cell, 15, 661, 10.1016/j.molcel.2004.08.024 Pan, 2016, The CBM complex underwrites NF-κB activation to promote HER2-associated tumor malignancy, Mol. Cancer Res., 14, 93, 10.1158/1541-7786.MCR-15-0229-T Patricelli, 2011, In situ kinase profiling reveals functionally relevant properties of native kinases, Chem. Biol., 18, 699, 10.1016/j.chembiol.2011.04.011 Post, 2017, Robust, sensitive, and automated phosphopeptide enrichment optimized for low sample amounts applied to primary hippocampal neurons, J. Proteome Res., 16, 728, 10.1021/acs.jproteome.6b00753 Ruprecht, 2015, Evaluation of kinase activity profiling using chemical proteomics, ACS Chem. Biol., 10, 2743, 10.1021/acschembio.5b00616 Sachs, 2018, A living biobank of breast cancer organoids captures disease heterogeneity, Cell, 172, 373, 10.1016/j.cell.2017.11.010 Schmidlin, 2016, Assessment of SRM, MRM(3), and DIA for the targeted analysis of phosphorylation dynamics in non-small cell lung cancer, Proteomics, 16, 2193, 10.1002/pmic.201500453 Sharifnia, 2014, Genetic modifiers of EGFR dependence in non-small cell lung cancer, Proc. Natl. Acad. Sci. USA, 111, 18661, 10.1073/pnas.1412228112 Shrivastava, 2011, Methods for the determination of limit of detection and limit of quantitation of the analytical methods, Chronicles Young Sci., 2, 21, 10.4103/2229-5186.79345 Soste, 2014, A sentinel protein assay for simultaneously quantifying cellular processes, Nat. Methods, 11, 1045, 10.1038/nmeth.3101 Stuhlmiller, 2015, Inhibition of Lapatinib-induced kinome reprogramming in ERBB2-positive breast cancer by targeting BET family bromodomains, Cell Rep., 11, 390, 10.1016/j.celrep.2015.03.037 Stuhlmiller, 2017, J. Am. Heart Assoc., 6 van den Eshof, 2017, Paradigm of biased PAR1 (protease-activated receptor-1) activation and inhibition in endothelial cells dissected by phosphoproteomics, Arterioscler. Thromb. Vasc. Biol., 37, 1891, 10.1161/ATVBAHA.117.309926 van Ramshorst, 2016, Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: the TRAIN-2 study, Breast, 29, 153, 10.1016/j.breast.2016.07.017 Wagle, 2011, Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling, J. Clin. Oncol., 29, 3085, 10.1200/JCO.2010.33.2312 Wagner, 2009, Signal integration by JNK and p38 MAPK pathways in cancer development, Nat. Rev. Cancer, 9, 537, 10.1038/nrc2694 Xiao, 2014, A targeted quantitative proteomics strategy for global kinome profiling of cancer cells and tissues, Mol. Cell. Proteomics, 13, 1065, 10.1074/mcp.M113.036905 Zagorac, 2018, In vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancer, Nat. Commun., 9, 3501, 10.1038/s41467-018-05742-z Zardavas, 2013, Emerging targeted agents in metastatic breast cancer, Nat. Rev. Clin. Oncol., 10, 191, 10.1038/nrclinonc.2013.29